open access

Ahead of print
Review paper
Published online: 2022-09-09
Get Citation

Avelumab use in Merkel cell carcinoma treatment

Monika Dudzisz-Śledź1, Martyna Zwierzchowska1, Elżbieta Bylina1, Piotr Rutkowski1, Anna M. Czarnecka1
DOI: 10.5603/NJO.a2022.0048
Affiliations
  1. Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland

open access

Ahead of print
Review article
Published online: 2022-09-09

Abstract

Avelumab is a programmed death-ligand 1 (PD-L1) blocking human IgG1 lambda monoclonal antibody. It was the first immunotherapy to be approved for the treatment of MCC. In March 2017, the FDA granted accelerated approval to avelumab for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC) irrespective of prior therapy. In July 2017, the European Medicines Agency (EMA) recommended the approval of avelumab as a monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma (mMCC). Approvals were based on the efficacy and safety demonstrated in JAVELIN Merkel 200 (NCT02155647), a multi-center, open-label, single-arm, phase II clinical trial [1]. Part A of the study consisted of patients treated in the second line with metastatic, chemotherapy-refractory MCC. Part B consisted of systemic treatment-naive patients who received avelumab as first-line treatment for metastatic or distally recurrent MCC. In the first line the ORR is 39.7%. Durable responses lasting at least 6 months were observed and the majority of responses are observed earlywith the median time to response of 6.1 week. PFS rate at 6 months and at 12 months are 41% and 31%, respectively. Median OS is 20.3 months. The OS rate at 1 year is 60%.

Abstract

Avelumab is a programmed death-ligand 1 (PD-L1) blocking human IgG1 lambda monoclonal antibody. It was the first immunotherapy to be approved for the treatment of MCC. In March 2017, the FDA granted accelerated approval to avelumab for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC) irrespective of prior therapy. In July 2017, the European Medicines Agency (EMA) recommended the approval of avelumab as a monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma (mMCC). Approvals were based on the efficacy and safety demonstrated in JAVELIN Merkel 200 (NCT02155647), a multi-center, open-label, single-arm, phase II clinical trial [1]. Part A of the study consisted of patients treated in the second line with metastatic, chemotherapy-refractory MCC. Part B consisted of systemic treatment-naive patients who received avelumab as first-line treatment for metastatic or distally recurrent MCC. In the first line the ORR is 39.7%. Durable responses lasting at least 6 months were observed and the majority of responses are observed earlywith the median time to response of 6.1 week. PFS rate at 6 months and at 12 months are 41% and 31%, respectively. Median OS is 20.3 months. The OS rate at 1 year is 60%.

Get Citation

Keywords

Merkel; avelumab; immunotherapy; skin

About this article
Title

Avelumab use in Merkel cell carcinoma treatment

Journal

Nowotwory. Journal of Oncology

Issue

Ahead of print

Article type

Review paper

Published online

2022-09-09

Page views

72

Article views/downloads

49

DOI

10.5603/NJO.a2022.0048

Keywords

Merkel
avelumab
immunotherapy
skin

Authors

Monika Dudzisz-Śledź
Martyna Zwierzchowska
Elżbieta Bylina
Piotr Rutkowski
Anna M. Czarnecka

References (29)
  1. Kaufman H, Russell J, Hamid O, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016; 17(10): 1374–1385.
  2. Becker J, Stang A, DeCaprio J, et al. Merkel cell carcinoma. Nat Rev Dis Primers. 2017; 3(1).
  3. Paulson KG, Park SY, Vandeven NA, et al. Merkel cell carcinoma: Current US incidence and projected increases based on changing demographics . J Am Acad Dermatol. 2018; 78(3): 457–463.e2.
  4. Becker JC, Stang A, Hausen AZ, et al. Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMEC. Cancer Immunol Immunother. 2018; 67(3): 341–351.
  5. Fitzgerald TL, Dennis S, Kachare SD, et al. Dramatic Increase in the Incidence and Mortality from Merkel Cell Carcinoma in the United States. Am Surg. 2015; 81(8): 802–806.
  6. Dudzisz-Śledź M, Zdzienicki M, Rutkowski P. Merkel cell carcinoma (MCC) – neuroendocrine skin cancer. Nowotwory. Journal of Oncology. 2019; 69(3-4): 111–116.
  7. Stachyra K, Dudzisz-Śledź M, Bylina E, et al. Merkel Cell Carcinoma from Molecular Pathology to Novel Therapies. Int J Mol Sci. 2021; 22(12).
  8. Feng H, Shuda M, Chang Y, et al. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science. 2008; 319(5866): 1096–1100.
  9. Heath M, Jaimes N, Lemos B, et al. Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features. J Am Acad Dermatol. 2008; 58(3): 375–381.
  10. Dudzisz-Sledz M, Sobczuk P, Kozak K, et al. Treatment of Locally Advanced Merkel Cell Carcinoma-A Multi-Center Study. Cancers (Basel). 2022; 14(2).
  11. Lemos B, Storer B, Iyer J, et al. Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: Analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol. 2010; 63(5): 751–761.
  12. Schmults CDD, Park S, Blitzblau R, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Merkel Cell Carcinoma Version 1.2021 — February 18, 2021. National Comprehensive Cancer Network: Plymouth Meeting, PA, USA 2021.
  13. Becker JC. Merkel cell carcinoma. Ann Oncol. 2010; 21: vii81–vii85.
  14. Chandra S, Zheng Y, Pandya S, et al. Real-world outcomes among US Merkel cell carcinoma patients initiating immune checkpoint inhibitors or chemotherapy. Future Oncol. 2020; 16(31): 2521–2536.
  15. Iyer JG, Blom A, Doumani R, et al. Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma. Cancer Med. 2016; 5(9): 2294–2301.
  16. Nghiem P, Bhatia S, Brohl A, et al. Two-year efficacy and safety update from JAVELIN Merkel 200 part A: A registrational study of avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy. J Clin Oncol. 2018; 36(15_suppl): 9507–9507.
  17. D'Angelo S, Russell J, Bhatia S, et al. 18-month efficacy and safety update from JAVELIN Merkel 200 part A: A phase II study of avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy. J Clin Oncol. 2018; 36(5_suppl): 192–192.
  18. Kaufman HL, Russell JS, Hamid O, et al. Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. J Immunother Cancer. 2018; 6(1): 7.
  19. D'Angelo SP, Bhatia S, Brohl AS, et al. Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial. J Immunother Cancer. 2020; 8(1).
  20. D'Angelo SP, Bhatia S, Brohl AS, et al. Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up. ESMO Open. 2021; 6(6): 100290.
  21. D'Angelo SP, Russell J, Lebbé C, et al. Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial. JAMA Oncol. 2018; 4(9): e180077.
  22. D'Angelo S, Russell J, Hassel J, et al. First-line (1L) avelumab treatment in patients (pts) with metastatic Merkel cell carcinoma (mMCC): Preliminary data from an ongoing study. J Clin Oncol. 2017; 35(15_suppl): 9530–9530.
  23. Bullement A, D'Angelo SP, Amin A, et al. Predicting overall survival in patients (pts) with treatment-naive metastatic Merkel cell carcinoma (mMCC) treated with avelumab . J Clin Oncol. 2018; 36(15_suppl): e21620–e21620.
  24. D'Angelo SP, Lebbé C, Mortier L, et al. First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study. J Immunother Cancer. 2021; 9(7).
  25. Nghiem P, Bhatia S, Lipson E, et al. Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy. J Clin Oncol. 2019; 37(9): 693–702.
  26. Correction: Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program. J Immunother Cancer. 2020; 8(1).
  27. Ascierto PA, Orlova K, Grignani G, et al. Avelumab expanded access program in metastatic Merkel cell carcinoma: Efficacy and safety findings from patients in Europe and the Middle East. Int J Cancer. 2021; 149(11): 1926–1934.
  28. Tai P, Au J. Skin cancer management-updates on Merkel cell carcinoma. Ann Transl Med. 2018; 6(14): 282.
  29. Bhatia S, Brohl A, Brownell I, et al. ADAM trial: A multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial of adjuvant avelumab (anti-PD-L1 antibody) in merkel cell carcinoma patients with clinically detected lymph node metastases; NCT03271372. J Clin Oncol. 2018; 36(15_suppl): TPS9605–TPS9605.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media sp. z o.o. VM Group sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl